solid start
net dbt
strong top-lin bottom-lin beat
report revenu beat consensu adjust
ep beat consensu product sale reduc expens
rais low end guidanc net product sale
adjust ep guidanc reflect
rang potenti sensipar gener competit outcom potenti competit
neulasta aranesp adjust non-gaap ep accordingli
maintain po multipl in-lin major pharma peer
reiter buy strong base busi
declin legaci product off-set double-digit growth new on-going
launch enbrel sale beat consensu project y-o-i
declin enbrel sale given slight decreas net price volum
neulasta sale came consensu expect
continu onpro util current make us unit
await eu approv prolia continu deliv remain signific growth driver
esa erythropoiesis-stimul agent franchis decreas due lower net sell
price increas competit overal pleas perform
end cash invest despit recent
buy-back believ plenti capac left right opportun
aris manag refus comment specif transform deal
believ thought disciplin compani open larg
transact long creat sharehold valu manag reiter focu
invest innov support intern drug launch upcom aimovig
return capit sharehold plan repurchas share
importantli early- mid-stag pipelin start show promis
gener clinic data next month believ intern
extern growth option command higher price-to-earnings unlock valu
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu
buy rate base belief
consensu revenu estim overestim
impact price pressur competit
top line addit new product
launch anticip biosimilar launch
help drive top-lin growth potenti
repatri signific portion
cash held oversea open door
potenti share buyback dividend payment
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer current trade
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
